Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / How Private Equity Is Consolidating Independent Optometry
Transcript
- Lucas: The eye doctor is one of those rare professions where you can still walk into a storefront and see a single sign with one name on it. But if you look at the transaction data from the last eighteen months, that solitary sign is disappearing faster than most people realize. Luna: It feels like every town has at least two or three optical shops now that used to be independent five years ago. Are we talking about national chains swallowing everyone, or is it more regional? Lucas: It is predominantly regional roll-ups. A private equity firm will identify a state or a multi-state corridor, acquire ten to fifteen practices over three years, and then optimize them as a single platform. The key asset here isn't just the patients; it's the supply chain leverage for frames and lenses. Luna: So the value creation comes from buying glass and plastic in bulk rather than relying on the individual doctor's purchasing power? Lucas: Exactly. An independent optometrist might order inventory from four different distributors. Once you consolidate that volume under one holding company, you negotiate direct contracts with major manufacturers. That margin expansion is what justifies the premium valuation multiple. Luna: That makes sense. It’s a classic playbook, but I wonder how hard it is to actually get these doctors to sell. Eye care seems like a very personal, community-focused business. Lucas: You hit on the central tension. Most independent optometrists are approaching retirement age. The median age of an owner-operator in this sector is pushing sixty-two. They have no successor inside the family, and they know their practice is their entire net worth. Luna: So it’s less about wanting to grow and more about wanting to cash out safely before interest rates make borrowing too expensive for expansion. Lucas: Precisely. In October 2026, capital costs are still elevated compared to the zero-rate era. Selling to a roll-up operator provides immediate liquidity and often includes earn-outs that allow the doctor to stay on for a transition period without taking on debt themselves. Luna: I’m curious about the customer experience though. When a local shop becomes part of a larger network, do the prices go down for consumers because of those efficiency gains? Lucas: It’s complicated. On the surface, standardized pricing looks good. But the real shift is in the product mix. Large platforms push proprietary lens coatings and higher-margin frame lines that independent stores simply couldn’t stock due to minimum order quantities. Luna: So you’re getting better variety and maybe slightly lower base prices, but you’re also steering patients toward branded products they might not have chosen otherwise? Lucas: That is the criticism. Critics argue that roll-ups turn personalized care into standardized retail. The doctor spends less time on diagnostics and more time hitting sales targets for specific frame collections. It’s a subtle change in incentive structure. Luna: Do you think there’s a limit to how many practices a single platform can own in one metro area before antitrust scrutiny kicks in? Lucas: Currently, there isn’t much federal enforcement specifically targeting optometry roll-ups. The Federal Trade Commission is focused on hospital mergers and big tech. Local markets are small enough that regulators rarely view a regional consolidator as a dominant force unless they control forty percent of a city. Luna: Forty percent is a high bar. Most cities don’t have that many independent clinics left to begin with. Lucas: Right. And even if they did, the barrier to entry for a new independent optometrist is rising. Insurance reimbursements for medical eye exams are stagnant, while the cost of running a physical location keeps climbing. It’s becoming harder to compete on pure clinical merit alone. Luna: Let me interject here for a moment. If you’ve found value in how we break down these niche industries, consider supporting the show directly. You can visit buy me a coffee dot com slash fexingo — that's F. E. X. I. N. G. O. A few dollars a month helps us keep digging into these deal flows without ads cluttering the conversation. Lucas: It really does matter. Your support allows us to spend time on research that isn’t just skimming headlines. It lets us look at the actual term sheets and understand the mechanics behind the news. Luna: Thanks for listening. Now, back to the economics of these acquisitions. What happens to the staff when a new management company takes over? Lucas: This is where the real friction occurs. Optical technicians and front-desk personnel are often retained initially, but performance metrics change rapidly. Turnover tends to spike in the first twelve months as new scheduling software and sales incentives are implemented. Luna: That sounds stressful for employees who were already doing fine. Do the platforms offer retention bonuses to keep them during that transition? Lucas: They usually do, but only for six to nine months. Once the new systems are fully integrated, the expectation is that the team adapts or leaves. It’s a clean-slate approach that prioritizes efficiency over institutional memory. Luna: I wonder if this affects the quality of care. If the experienced technicians leave, does the diagnostic accuracy suffer? Lucas: There is evidence of that. Patient satisfaction scores often dip in the year following acquisition. However, clinical outcomes for routine vision correction remain stable. The issue is more about trust and continuity than actual medical error. Luna: So patients might feel less comfortable, but they aren’t necessarily getting worse glasses. It’s a service degradation rather than a quality failure. Lucas: Exactly. And that distinction matters for investors. As long as prescriptions are accurate and frames fit, the revenue stream holds. Emotional loyalty is fragile, but functional necessity is sticky. Luna: What about the digital side? Are these roll-ups trying to integrate telemedicine or online consultations to reduce foot traffic? Lucas: Some are experimenting with hybrid models, but eye care is inherently physical. You need to try on frames. You need a retinal scan. Telemedicine can handle follow-ups, but it cannot replace the showroom experience that drives the majority of revenue. Luna: That makes sense. The store is essentially a warehouse for experiences. Without the physical interaction, the whole model collapses. Lucas: Correct. This limits how far these platforms can expand without heavy capital expenditure. They cannot simply scale software; they must lease or buy physical space in every neighborhood they target. Luna: Does that real estate burden slow down growth? It seems like a heavy asset model compared to something like dental services organizations. Lucas: It does. Dental offices often have specialized equipment that is easier to standardize across locations. Optical requires significant floor space for displays and fitting rooms. That density requirement caps the speed of consolidation. Luna: So we might see slower, more deliberate roll-ups in optometry compared to other healthcare sectors. Quality over quantity. Lucas: I would say quality is secondary to regional dominance. The goal is to own the best corridors. Once you control the main streets in a county, you dictate the terms for suppliers and insurers alike. Luna: It reminds me of how grocery stores operate. Once you’re the only option in a strip mall, you set the price. Lucas: A fair comparison. Except in optometry, you rarely have a choice. If your insurance network excludes the local independent shop, you have to go where the contract exists. Luna: Insurance networks are the invisible hand guiding this consolidation. Patients don’t choose the provider; the payer chooses for them. Lucas: Precisely. And payers prefer providers who can guarantee availability and consistent billing practices. Roll-ups offer that predictability. Independent practices are viewed as risky partners because their financial health fluctuates with individual doctor decisions. Luna: So the private equity firms are selling stability to both doctors and insurers. It’s a win-win for the businesses involved, even if it reduces local autonomy. Lucas: For the sellers, it is absolutely a win. For the industry, it creates a more efficient, if less diverse, ecosystem. We’ll likely see this trend accelerate through the end of the decade. Luna: One final question. For someone watching this, should they be worried about their local eye doctor vanishing, or is it just a normal cycle of business evolution? Lucas: It is a normal cycle. But it is worth knowing that the person behind the counter may soon answer to a boardroom rather than a neighbor. The convenience remains, but the connection changes. Luna: That’s a sobering way to end it. Thanks for breaking down the mechanics of the roll-up. Lucas: My pleasure. Keep an eye on those regional players next time you renew your prescription.